Trial Outcomes & Findings for A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors (NCT NCT01248949)

Last Updated: 2017-03-29

Results Overview

DLT was defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

162 participants

Primary outcome timeframe

From the time of first administration of MEDI3617 single agent or MEDI3617 combination therapy through the first 21-day or 28-day cycle (Cycle 1)

Results posted on

2017-03-29

Participant Flow

A total of 162 participants were screened, of which 46 did not meet eligibility criteria and were considered as screen failures; the remaining 116 participants entered into the study and treated with MEDI3617.

Participant milestones

Participant milestones
Measure	MEDI3617 SINGLE AGENT TOTAL Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/ PACLITAXEL TOTAL Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Overall Study STARTED	42	16	38	13	7
Overall Study COMPLETED	9	3	1	3	3
Overall Study NOT COMPLETED	33	13	37	10	4

Reasons for withdrawal

Reasons for withdrawal
Measure	MEDI3617 SINGLE AGENT TOTAL Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/ PACLITAXEL TOTAL Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Overall Study Lost to Follow-up	2	2	2	1	0
Overall Study Withdrawal by Subject	5	3	11	3	1
Overall Study Death	22	7	21	6	2
Overall Study Alternative Therapy	1	0	0	0	0
Overall Study Alternative Therapy.	1	0	0	0	0
Overall Study Palliative Radiation To Brain Metastases	1	0	0	0	0
Overall Study Entered Hospice And Refused Follow Up	0	0	0	0	1
Overall Study Participant Went To Hospice	0	0	1	0	0
Overall Study Per Sponsor Request o Discontinue Drug	1	0	0	0	0
Overall Study Pi Decision Due To Declining Status	0	0	1	0	0
Overall Study Pi Discretion Due To Hospitalisation	0	1	0	0	0
Overall Study Lesion In ThoracicSpine Requires Therapy	0	0	1	0	0

Baseline Characteristics

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.	Total n=116 Participants Total of all reporting groups
Age, Continuous	61.4 Years STANDARD_DEVIATION 12.4 • n=5 Participants	57.4 Years STANDARD_DEVIATION 11.9 • n=7 Participants	57.7 Years STANDARD_DEVIATION 11.2 • n=5 Participants	60.4 Years STANDARD_DEVIATION 12.7 • n=4 Participants	56.7 Years STANDARD_DEVIATION 12.3 • n=21 Participants	59.2 Years STANDARD_DEVIATION 11.9 • n=8 Participants
Sex: Female, Male Female	27 Participants n=5 Participants	7 Participants n=7 Participants	18 Participants n=5 Participants	8 Participants n=4 Participants	5 Participants n=21 Participants	65 Participants n=8 Participants
Sex: Female, Male Male	15 Participants n=5 Participants	9 Participants n=7 Participants	20 Participants n=5 Participants	5 Participants n=4 Participants	2 Participants n=21 Participants	51 Participants n=8 Participants

PRIMARY outcome

Timeframe: From the time of first administration of MEDI3617 single agent or MEDI3617 combination therapy through the first 21-day or 28-day cycle (Cycle 1)

Population: DLT Evaluable population included all participants enrolled in dose-escalation, who received at least 1 full assigned dose of single-agent MEDI3617 or full assigned doses of MEDI3617 and standard therapeutic agents on Cycle 1 and completed safety follow-up or experienced a DLT at any point during the 21-day or 28-day DLT evaluation period.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=23 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=15 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=22 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=11 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=6 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With Dose Limiting Toxicities (DLTs)	1 Participants	1 Participants	2 Participants	1 Participants	1 Participants

PRIMARY outcome

Timeframe: From the time of first administration of MEDI3617 single agent or MEDI3617 combination therapy through the first 21-day or 28-day cycle (Cycle 1)

The dose-escalation phase used a 3 + 3 design. If greater than or equal to 2 (≥ 2) participants in a dose cohort experienced a DLT during the DLT period, the MTD was exceeded and no further participants were enrolled into that dose cohort. If this occurred, the preceding dose cohort was evaluated for the MTD and a total of 6 participants were treated at the preceding dose. If less than or equal to 1 (≤ 1) of 6 participants experienced a DLT at the preceding dose, then this dose level was the MTD. DLTs were defined as any treatment-related, grade 3 or higher toxicity (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 4.0); occurring during the first 21 or 28 days after the initial administration of MEDI3617.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=23 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=15 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=22 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=11 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=6 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Maximum Tolerated Dose (MTD)	NA milligram (mg) The highest dose level was cleared and the MTD was not reached.	NA milligram (mg) A DLT was reported at the highest dose level, but only 5 out of the 6 participants enrolled were evaluable for DLT. Thus, it is unclear if the MTD was exceeded or reached at the highest dose level tested.	NA milligram (mg) The highest dose level was cleared and the MTD was not reached.	NA milligram (mg) The highest dose level was cleared and the MTD was not reached.	NA milligram (mg) A DLT was reported at the highest dose level, but it is unclear if the MTD was exceeded or reached, as only 3 participants were enrolled (all participants were evaluable for DLT).

PRIMARY outcome

Timeframe: From start of study drug administration up to 90 days after the last dose of MEDI3617

Population: Safety population included all participants who received treatment with MEDI3617.

An adverse event (AE) was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events occurring after administration of investigational product.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) TEAEs	42 Participants	16 Participants	38 Participants	13 Participants	7 Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) TESAEs	18 Participants	4 Participants	18 Participants	7 Participants	4 Participants

PRIMARY outcome

Timeframe: From start of study drug administration up to 90 days after the last dose of MEDI3617

Population: Safety population included all participants who received treatment with MEDI3617.

Laboratory evaluations were performed, including hematology and serum chemistry. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to laboratory abnormalities were recorded and reported.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Blood urea increased	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Alanine aminotransferase increased	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Aspartate aminotransferase increased	0 Participants	1 Participants	2 Participants	1 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Blood alkaline phosphatase increased	1 Participants	0 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Blood creatinine increased	2 Participants	1 Participants	2 Participants	1 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Blood lactate dehydrogenase increased	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Blood potassium increased	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Blood triglycerides increased	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) Hematology: Anemia	5 Participants	1 Participants	1 Participants	3 Participants	2 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) Hematology: Leukopenia	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) Hematology: Neutropenia	1 Participants	0 Participants	0 Participants	0 Participants	3 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) Hematology: Thombocytopenia	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) Hematology: White blood cell count decreased	2 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Gamma-glutamyltransferase increased	1 Participants	1 Participants	1 Participants	1 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hyperglycaemia	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hyperkalaemia	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hypertriglyceridaemia	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hyperuricaemia	1 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hypoalbuminaemia	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hypocalcaemia	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hypoglycaemia	1 Participants	1 Participants	2 Participants	0 Participants	0 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hypokalaemia	3 Participants	0 Participants	2 Participants	0 Participants	1 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hypomagnesaemia	1 Participants	1 Participants	0 Participants	1 Participants	3 Participants
Number of Participants With Laboratory Abnormalities Recorded as Adverse Events (AEs) SerChem: Hyponatremia	0 Participants	2 Participants	1 Participants	1 Participants	2 Participants

PRIMARY outcome

Timeframe: From start of study drug administration up to 90 days after the last dose of MEDI3617

Population: Safety population included all participants who received treatment with MEDI3617.

Vital signs included parameters such as heart rate, blood pressure, temperature, weight and respiratory rate. An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to vital signs abnormalities were recorded and reported.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Arrhythmia	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Sinus tachycardia	0 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Tachycardia	1 Participants	1 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Pyrexia	3 Participants	3 Participants	1 Participants	0 Participants	1 Participants
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Weight decreased	0 Participants	2 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Weight increased	9 Participants	2 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Hypertension	10 Participants	7 Participants	13 Participants	3 Participants	2 Participants
Number of Participants With Vital Sign Abnormalities Recorded as Adverse Events (AEs) Hypotension	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: From start of study drug administration up to 90 days after the last dose of MEDI3617

Population: Safety population included all participants who received treatment with MEDI3617.

An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to echocardiogram abnormalities were recorded and reported. The only AE reported was ejection fraction decreased in the MEDI3617 + Paclitaxel total group.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With Echocardiogram Abnormalities Recorded as Adverse Events (AEs)	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants

PRIMARY outcome

Timeframe: From start of study drug administration up to 90 days after the last dose of MEDI3617

Population: Safety population included all participants who received treatment with MEDI3617

An AE was any untoward medical occurrence in a participant administered investigational product and which does not necessarily have a causal relationship with this treatment. AEs related to electrocardiogram abnormalities were recorded and reported. The only AE reported was electrocardiogram QT prolonged in the MEDI3617 + Bevacizumab Q2W total group.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With Electrocardiogram Abnormalities Recorded as Adverse Events (AEs)	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants

PRIMARY outcome

Timeframe: From start of study drug administration up to 30 days after the last dose of MEDI3617

Population: Safety population included all participants who received treatment with MEDI3617

KPS scale: 100 is no evidence of disease; 90 is able to carry on normal activity, minor symptoms of disease; 80 is normal activity with effort, some symptoms of disease; 70 is cares for self; unable to do active work; 60 is requires occasional assistance, but is able to care for most of his needs; 50 is requires considerable assistance with frequent medical care; 40 is disabled, requires special care; 30 is severely disabled, hospitalization is indicated although death is not imminent; 20 is very sick, hospitalization necessary, active support treatment necessary; 10 is moribund, fatal processes progressing rapidly, 0 is dead.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With a Decline in Karnofsky Performance Status (KPS) of ≥ 20 Points at Worst Record On-study Compared With Baseline	11 Participants	6 Participants	7 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Days 1, 2 (MEDI3617 single agent only), 4, 8, 15 (Cycle 1); Day 1 (Cycle 2 and every cycle after), Day 15 (MEDI3617 + bev Q2W and MEDI3617 + paclitaxel only, Cycle 2 and every cycle after); end of treatment; 30 days and 3 months post last dose

Population: All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.

Cmax is the maximum observed serum concentration of MEDI3617. Here, "n" is number of participants analyzed for this endpoint at a specific dose.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=41 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=35 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort -2 (n=3)	1.39 microgram per milliliter (mcg/ml) Standard Deviation 0.254	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort -1 (n=2)	2.44 microgram per milliliter (mcg/ml) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort 1 (n=6)	6.63 microgram per milliliter (mcg/ml) Standard Deviation 3.48	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort 2 (n=3)	50.2 microgram per milliliter (mcg/ml) Standard Deviation 28.8	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort 3 (n=3)	82.4 microgram per milliliter (mcg/ml) Standard Deviation 2.68	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort 4 (n=3)	239 microgram per milliliter (mcg/ml) Standard Deviation 79.5	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort 5 (n=4)	785 microgram per milliliter (mcg/ml) Standard Deviation 189	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort ovarian cancer expansion (OCE) -1 (n=15)	336 microgram per milliliter (mcg/ml) Standard Deviation 62.2	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort OCE 1 (n=2)	346 microgram per milliliter (mcg/ml) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 1A (n=4)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	30.4 microgram per milliliter (mcg/ml) Standard Deviation 26.8	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 2A (n=3)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	55.3 microgram per milliliter (mcg/ml) Standard Deviation 12.6	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 3A (n=3)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	235 microgram per milliliter (mcg/ml) Standard Deviation 90.5	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 4A (n=6)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	348 microgram per milliliter (mcg/ml) Standard Deviation 54.6	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 1B (n=7)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	44.5 microgram per milliliter (mcg/ml) Standard Deviation 39.3	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 2B (n=3)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	47.5 microgram per milliliter (mcg/ml) Standard Deviation 23.3	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 3B (n=8)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	116 microgram per milliliter (mcg/ml) Standard Deviation 35.1	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MB 4B (n=8)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	275 microgram per milliliter (mcg/ml) Standard Deviation 86.2	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort TT2A (n=9)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.	320 microgram per milliliter (mcg/ml) Standard Deviation 170	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MP1 (n=7)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	114 microgram per milliliter (mcg/ml) Standard Deviation 22.5	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MP2 (n=6)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	209 microgram per milliliter (mcg/ml) Standard Deviation 57.4	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MCP1 (n=4)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	200 microgram per milliliter (mcg/ml) Standard Deviation 25.8
Maximum Observed Serum Concentration (Cmax) of MEDI3617 Cohort MCP2 (n=3)	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA microgram per milliliter (mcg/ml) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	585 microgram per milliliter (mcg/ml) Standard Deviation 491

SECONDARY outcome

Population: All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.

AUC0-last is the Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration of MEDI3617. Here, "n" is number of participants analyzed for this endpoint at a specific dose.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=41 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=35 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort OCE -1 (n=15)	2610 day*mcg/mL Standard Deviation 891	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort -2 (n=3)	1.3 day*mcg/mL Standard Deviation 0.429	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort -1 (n=2)	2.2 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort 1 (n=6)	11.9 day*mcg/mL Standard Deviation 11.8	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort 2 (n=3)	171 day*mcg/mL Standard Deviation 69	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort 3 (n=3)	438 day*mcg/mL Standard Deviation 204	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort 4 (n=3)	2610 day*mcg/mL Standard Deviation 1570	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort 5 (n=4)	3650 day*mcg/mL Standard Deviation 2600	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort OCE 1 (n=2)	2160 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 1A (n=4)	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	101 day*mcg/mL Standard Deviation 48.8	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 2A (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	473 day*mcg/mL Standard Deviation 223	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 3A (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	2280 day*mcg/mL Standard Deviation 529	NA day*mcg/mL Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 4A (n=6)	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	2710 day*mcg/mL Standard Deviation 1070	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 1B (n=7)	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	94.7 day*mcg/mL Standard Deviation 48.7	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 2B (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	216 day*mcg/mL Standard Deviation 61.8	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 3B (n=8)	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	805 day*mcg/mL Standard Deviation 292	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MB 4B (n=8)	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	2310 day*mcg/mL Standard Deviation 941	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort TT2A (n=9)	NA day*mcg/mL Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.	2590 day*mcg/mL Standard Deviation 1920	NA day*mcg/mL Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort TT2A (participants with bevacizumab-refractory glioma), was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MP1 (n=7)	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	551 day*mcg/mL Standard Deviation 331	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MP2 (n=6)	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	1460 day*mcg/mL Standard Deviation 484	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MCP1 (n=4)	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	1240 day*mcg/mL Standard Deviation 882
Area Under the Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI3617 Cohort MCP2 (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	2890 day*mcg/mL Standard Deviation 257

SECONDARY outcome

Population: All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.

The AUC0-inf is the Area Under the Concentration-Time Curve From Time Zero to infinity of MEDI3617. Here, "n" is number of participants analyzed for this endpoint at a specific dose.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=25 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=8 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=13 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=4 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=3 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MCP1 (n=1)	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	2240 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MP1 (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	849 day*mcg/mL Standard Deviation 163	NA day*mcg/mL Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MP2 (n=1)	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	2810 day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort OCE -1 (n=12)	3280 day*mcg/mL Standard Deviation 1410	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort OCE 1 (n=2)	2490 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MB 1A (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	110 day*mcg/mL Standard Deviation 58.1	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MB 2A (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	628 day*mcg/mL Standard Deviation 376	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MB 4A (n=2)	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	3920 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MB 1B (n=7)	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	104 day*mcg/mL Standard Deviation 61	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MB 2B (n=3)	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	252 day*mcg/mL Standard Deviation 83.2	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MB 3B (n=2)	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	1200 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MB 4B (n=1)	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	4630 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day*mcg/mL Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort -2 (n=1)	1.79 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort 1 (n=1)	8.12 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group	NA day*mcg/mL Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort 2 (n=2)	269 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort 3 (n=3)	529 day*mcg/mL Standard Deviation 269	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort 4 (n=2)	2150 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort 5 (n=2)	4230 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day*mcg/mL Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MEDI3617 Cohort MCP2 (n=2)	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day*mcg/mL Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	3560 day*mcg/mL Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).

SECONDARY outcome

Population: All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.

Systemic clearance describes the removal of drug from a volume of serum in a given unit of time (drug loss from the body). It is measured as milliliter per day (mL/day). Here, "n" is number of participants analyzed for this endpoint at a specific dose.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=25 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=8 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=13 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=4 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=3 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Systemic Clearance (CL) of MEDI3617 Cohort OCE -1 (n=12)	352 milliliter per day (mL/day) Standard Deviation 136	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort MB 1A (n=3)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	1060 milliliter per day (mL/day) Standard Deviation 426	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Systemic Clearance (CL) of MEDI3617 Cohort MB 1B (n=7)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	797 milliliter per day (mL/day) Standard Deviation 499	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Systemic Clearance (CL) of MEDI3617 Cohort -2 (n=1)	2790 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort 1 (n=1)	2460 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort 2 (n=2)	423 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort 3 (n=3)	679 milliliter per day (mL/day) Standard Deviation 345	NA milliliter per day (mL/day) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort 4 (n=2)	465 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort 5 (n=2)	355 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort OCE 1 (n=2)	603 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.
Systemic Clearance (CL) of MEDI3617 Cohort MB 2A (n=3)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	614 milliliter per day (mL/day) Standard Deviation 363	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Systemic Clearance (CL) of MEDI3617 Cohort MB 4A (n=2)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	388 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Systemic Clearance (CL) of MEDI3617 Cohort MB 2B (n=3)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	847 milliliter per day (mL/day) Standard Deviation 237	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Systemic Clearance (CL) of MEDI3617 Cohort MB 3B(n=2)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	501 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Systemic Clearance (CL) of MEDI3617 Cohort MB 4B (n=1)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	216 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Systemic Clearance (CL) of MEDI3617 Cohort MP1 (n=3)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	727 milliliter per day (mL/day) Standard Deviation 157	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
Systemic Clearance (CL) of MEDI3617 Cohort MP2 (n=1)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	356 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA milliliter per day (mL/day) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
Systemic Clearance (CL) of MEDI3617 Cohort MCP1 (n=1)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	446 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).
Systemic Clearance (CL) of MEDI3617 Cohort MCP2 (n=2)	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA milliliter per day (mL/day) Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	424 milliliter per day (mL/day) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).

SECONDARY outcome

Population: All participants who received treatment with MEDI3617 and for whom PK blood samples were collected and evaluated.

The t1/2 is the time in days required for the concentration of the drug to reach half of its original value. Here, "n" is number of participants analyzed for this endpoint at a specific dose.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=25 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=8 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=13 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=4 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=3 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MB 4B (n=1)	NA day Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	10.2 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort -2 (n=1)	0.585 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort 1 (n=1)	1.26 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort 2 (n=2)	5.86 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort 3 (n=3)	5.98 day Standard Deviation 3.09	NA day Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort 4 (n=2)	7.68 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort 5 (n=2)	7.79 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort OCE -1 (n=12)	10.4 day Standard Deviation 3.15	NA day Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort OCE 1 (n=2)	9.03 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.	NA day Standard Deviation NA Cohort OCE 1 was part of the MEDI3617 Single agent total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MB 1A (n=3)	NA day Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	3.59 day Standard Deviation 0.983	NA day Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MB 2A (n=3)	NA day Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	9.67 day Standard Deviation 3.35	NA day Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MB 4A (n=2)	NA day Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	12.3 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA day Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MB 1B (n=7)	NA day Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	3.9 day Standard Deviation 2.69	NA day Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MB 2B (n=3)	NA day Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	5.12 day Standard Deviation 0.541	NA day Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MB 3B(n=2)	NA day Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	8.23 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA day Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MP1 (n=3)	NA day Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA day Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA day Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	6.96 day Standard Deviation 1.59	NA day Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MP2 (n=1)	NA day Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA day Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA day Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	9.34 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA day Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MCP1 (n=1)	NA day Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	15.1 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).
Terminal Elimination Half Life (t1/2) of MEDI3617 Cohort MCP2 (n=2)	NA day Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA day Standard Deviation NA Cohort MCP2 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	11.1 day Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).

SECONDARY outcome

Timeframe: Presence of ADA to MEDI3617 were assessed prior to infusion with MEDI3617 on Day 1 of each dosing cycle, as well as the end of treatment, and 30 days, 3 months, and 6 months post last dose of MEDI3617

Population: All participants who received treatment with MEDI3617.

The immunogenic potential of MEDI3617 was assessed by summarizing the number and percentage of participants who develop detectable ADA. Immunogenicity assessment included determination of anti-drug (MEDI3617) antibodies in serum samples. Samples were measured for the presence of ADA using validated immunoassays.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Number of Participants With Positive Anti-Drug Antibody (ADA)	0 participants	0 participants	0 participants	0 participants	0 participants

SECONDARY outcome

Timeframe: Time from the first dose of investigational product until end of study

Population: Safety population included all participants who received treatment with MEDI3617.

Objective response rate defined as the number of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (\<) 10 millimeter (the sum may not be "0" if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Objective Response Rate (ORR)	1 Participants	1 Participants	2 Participants	2 Participants	0 Participants

SECONDARY outcome

Timeframe: Time from the first dose of investigational product until end of study

Population: Safety population included all participants who received treatment with MEDI3617.

Time to response (TTR) is defined as the time from the study entry to the first documentation of confirmed CR or confirmed PR. CR was defined as disappearance of all target lesions, any pathological lymph nodes must have reduction in short axis to less than (\<) 10 millimeter (the sum may not be "0" if there are target nodes). PR was defined as at least a 30 percent (%) decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Analysis was based on responses confirmed at a repeat assessment made at least 4 weeks after the initial response, with the TTR taken as the first time the response was observed, not the confirmation assessment. TTR was evaluated using the Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Time to Response (TTR)	2.6 months Interval 2.6 to 2.6	1.2 months Interval 1.2 to 1.2	2.0 months Interval 1.6 to 2.3	1.7 months Interval 1.6 to 1.7	NA months No objective response was observed in the MEDI3617 + carboplatin/paclitaxel cohorts.

SECONDARY outcome

Timeframe: Time from the first dose of investigational product until end of study

Population: Safety population included all participants who received treatment with MEDI3617.

Duration of response is defined as the duration from the first documentation of objective disease response (ie, confirmed CR or confirmed PR) to the first documented disease progression. The duration of response was censored on the date of last tumor assessment documenting absence of disease progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Duration of response was evaluated for the subgroup of participants with an objective response using the Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Duration of Response (DOR)	3.7 months Interval 3.7 to 3.7	NA months Interval 17.8 to 17.8 Due to the lack of available data caused by censoring subjects in the MEDI3617 + bevacizumab Q3W escalation cohorts for this endpoint, median duration of response was not calculable.	NA months Interval 2.9 to 3.7 Due to the lack of available data caused by censoring subjects in the MEDI3617 + bevacizumab Q2W cohorts for this endpoint, median duration of response was not calculable.	NA months Interval 1.6 to 17.7 Due to the lack of available data caused by censoring subjects in the MEDI3617 + paclitaxel cohorts for this endpoint, median duration of response was not calculable.	NA months No objective response was observed in the MEDI3617 + carboplatin/paclitaxel cohorts.

SECONDARY outcome

Timeframe: Time from the first dose of investigational product until end of study

Population: Safety population included all participants who received treatment with MEDI3617.

Time to progression (TTP) is defined as time from the start of treatment with MEDI3617 until the documentation of disease progression. The TTP was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had TTP censored on the first date of treatment with MEDI3617. TTP was evaluated using the Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Time to Progression (TTP)	1.4 months Interval 0.0 to 8.6	11.4 months Interval 0.0 to 39.4	1.8 months Interval 0.0 to 5.3	3.5 months Interval 0.0 to 19.4	NA months Interval 0.0 to 4.0 Due to the lack of available data caused by censoring subjects in the MEDI3617 + carboplatin/paclitaxel cohorts for this endpoint, median time to progression was not calculable.

SECONDARY outcome

Timeframe: Time from the first dose of investigational product until end of study

Population: Safety population included all participants who received treatment with MEDI3617.

PFS was measured from the start of treatment with MEDI3617 until the documentation of disease progression or death due to any cause, whichever occurred first. PFS was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression and were still alive prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Participants having no tumor assessments after the start of treatment with MEDI3617 had PFS censored on the first date of treatment with MEDI3617. PFS was evaluated using the Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Progression-Free Survival (PFS)	1.4 months Interval 0.0 to 8.6	11.4 months Interval 0.0 to 39.4	1.7 months Interval 0.0 to 5.3	3.5 months Interval 0.0 to 19.4	NA months Interval 0.0 to 4.0 Due to the lack of available data caused by censoring subjects in the MEDI3617 + carboplatin/paclitaxel cohorts for this endpoint, median progression-free survival was not calculable.

SECONDARY outcome

Timeframe: Time from the first dose of investigational product until death due to any cause

Population: Safety population included all participants who received treatment with MEDI3617.

Overall survival is defined as the time from the start of treatment with MEDI3617 until death. For the participants who were alive at the end of study or lost to follow-up, overall survival was censored on the last date when participants were known to be alive. Overall survival was evaluated using the Kaplan-Meier method.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=42 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=13 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Overall Survival (OS)	11.4 months Interval 0.3 to 46.8	25.7 months Interval 1.3 to 42.8	7.4 months Interval 0.5 to 33.4	14.2 months Interval 1.0 to 35.7	NA months Interval 1.9 to 34.4 Due to the lack of available data caused by censoring subjects in the MEDI3617 + carboplatin/paclitaxel cohorts for this endpoint, median overall survival was not calculable.

SECONDARY outcome

Timeframe: Prior to infusion on Cycle 4 and Cycle 5

Population: All participants who received treatment with MEDI3617 and for whom PD blood samples were collected and evaluated.

Profile of Ang2 post MEDI3617 administration in relation to time course of antibody concentrations.

Outcome measures

Outcome measures
Measure	MEDI3617 SINGLE AGENT TOTAL n=14 Participants Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=11 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=7 Participants Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + PACLITAXEL TOTAL n=3 Participants Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=2 Participants Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort -2 (n=2)	4.07 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort -2 (n=2)	4.28 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -2 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort -1 (n=2)	5.11 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort -1 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort 1 (n=3)	5.69 nanogram per millileter (ng/mL) Standard Deviation 4.02	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort 1 (n=2)	8.22 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 1 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort 2 (n=1)	307.53 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort 2 (n=1)	924.66 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 2 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort 3 (n=1)	341.21 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort 3 (n=1)	265.86 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 3 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort 4 (n=1)	288.10 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 4 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort 5 (n=1)	1181.14 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort 5 (n=1)	1451.43 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort 5 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort OCE -1 (n=3)	312.27 nanogram per millileter (ng/mL) Standard Deviation 151.19	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort OCE -1 (n=3)	206.43 nanogram per millileter (ng/mL) Standard Deviation 83.74	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort OCE -1 was part of the MEDI3617 Single agent total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MB 1A (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	386.13 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MB 1A (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	421.74 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MB 2A (n=3)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	215.71 nanogram per millileter (ng/mL) Standard Deviation 143.16	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MB 2A (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	228.92 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MB 3A (n=1)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	218.48 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MB 3A (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	247.51 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MB 4A (n=4)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	368.08 nanogram per millileter (ng/mL) Standard Deviation 257.59	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MB 4A (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	353.73 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4A was part of the MEDI3617 + Bevacizumab Q3W escalation group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MB 1B (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	466.27 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MB 1B (n=1)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	750.61 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 1B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MB 2B (n=1)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	421.03 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MB 2B (n=1)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	387.45 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 2B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4:Cohort MB 3B (n=1)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	141.93 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 3B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MB 4B (n=3)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	229.19 nanogram per millileter (ng/mL) Standard Deviation 109.02	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MB 4B (n=1)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	174.65 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MB 4B was part of the MEDI3617 + Bevacizumab Q2W Total group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MP1 (n=1)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.	339.35 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP1 was part of the MEDI3617 + Paclitaxel group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MP2 (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	210.43 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MP2 (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.	166.73 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MP2 was part of the MEDI3617 + Paclitaxel group.
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 4: Cohort MCP1 (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	348.53 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).
Circulating Levels of Angiopoietin 2 (Ang2) Cycle 5: Cohort MCP1 (n=2)	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	NA nanogram per millileter (ng/mL) Standard Deviation NA Cohort MCP1 was part of the MEDI3617 + Carboplatin/Paclitaxel group.	336.31 nanogram per millileter (ng/mL) Standard Deviation NA Standard deviation was not calculated due to limited sample size (n\<3).

Adverse Events

MEDI3617 + PACLITAXEL TOTAL

Serious events: 7 serious events

Other events: 13 other events

Deaths: 0 deaths

MEDI3617 SINGLE AGENT TOTAL

Serious events: 18 serious events

Other events: 40 other events

Deaths: 0 deaths

MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL

Serious events: 4 serious events

Other events: 16 other events

Deaths: 0 deaths

MEDI3617 + BEVACIZUMAB Q2W TOTAL

Serious events: 18 serious events

Other events: 34 other events

Deaths: 0 deaths

MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL

Serious events: 4 serious events

Other events: 7 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	MEDI3617 + PACLITAXEL TOTAL n=13 participants at risk Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 SINGLE AGENT TOTAL n=42 participants at risk Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 participants at risk Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 participants at risk Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 participants at risk Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Blood and lymphatic system disorders Anaemia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Blood and lymphatic system disorders Neutropenia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Cardiac disorders Atrial fibrillation	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Cardiac disorders Cardiac arrest	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Abdominal pain	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Ascites	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Dysphagia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Faecal incontinence	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Intestinal obstruction	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Nausea	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Pancreatitis acute	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Vomiting	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Asthenia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Medical device pain	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Oedema	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Oedema peripheral	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Pyrexia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Immune system disorders Anaphylactic reaction	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Immune system disorders Drug hypersensitivity	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Infections and infestations Abscess limb	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Infections and infestations Meningitis	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Infections and infestations Pneumonia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Infections and infestations Urinary tract infection	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Blood alkaline phosphatase increased	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Blood creatinine increased	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Ejection fraction decreased	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Troponin increased	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Weight increased	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Decreased appetite	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Dehydration	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Failure to thrive	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Glioblastoma	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Aphasia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Ataxia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Cerebrovascular accident	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Cognitive disorder	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Encephalopathy	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Headache	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Hemiparesis	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Ischaemic stroke	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Memory impairment	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Posterior reversible encephalopathy syndrome	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Seizure	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Syncope	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Psychiatric disorders Confusional state	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Renal and urinary disorders Dysuria	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Renal and urinary disorders Nephrotic syndrome	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Renal and urinary disorders Renal failure	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Renal and urinary disorders Urinary incontinence	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Renal and urinary disorders Urinary tract obstruction	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Reproductive system and breast disorders Female genital tract fistula	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Reproductive system and breast disorders Pelvic pain	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Chylothorax	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Pneumonitis	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Vascular disorders Deep vein thrombosis	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Vascular disorders Embolism	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Vascular disorders Haematoma	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Vascular disorders Hypertension	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Vascular disorders Lymphoedema	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617

Other adverse events

Other adverse events
Measure	MEDI3617 + PACLITAXEL TOTAL n=13 participants at risk Participants received MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 SINGLE AGENT TOTAL n=42 participants at risk Participants received MEDI3617 via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q3W ESCALATION TOTAL n=16 participants at risk Participants received MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.	MEDI3617 + BEVACIZUMAB Q2W TOTAL n=38 participants at risk Participants received MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.	MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL n=7 participants at risk Participants received MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
Blood and lymphatic system disorders Anaemia	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Cardiac disorders Atrial fibrillation	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Eye disorders Vision blurred	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Abdominal distension	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Abdominal pain	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	16.7% 7/42 • Number of events 7 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Ascites	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Constipation	30.8% 4/13 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	38.1% 16/42 • Number of events 19 • From start of study drug administration up to 90 days after the last dose of MEDI3617	56.2% 9/16 • Number of events 12 • From start of study drug administration up to 90 days after the last dose of MEDI3617	10.5% 4/38 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Diarrhoea	30.8% 4/13 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	19.0% 8/42 • Number of events 11 • From start of study drug administration up to 90 days after the last dose of MEDI3617	31.2% 5/16 • Number of events 7 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Dry mouth	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	16.7% 7/42 • Number of events 7 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Dyspepsia	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Dysphagia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Gingival pain	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Nausea	30.8% 4/13 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	26.2% 11/42 • Number of events 13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	50.0% 8/16 • Number of events 14 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.9% 11/38 • Number of events 13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	57.1% 4/7 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Gastrointestinal disorders Vomiting	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	26.2% 11/42 • Number of events 14 • From start of study drug administration up to 90 days after the last dose of MEDI3617	31.2% 5/16 • Number of events 8 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Chills	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Fatigue	38.5% 5/13 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	42.9% 18/42 • Number of events 26 • From start of study drug administration up to 90 days after the last dose of MEDI3617	62.5% 10/16 • Number of events 13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	31.6% 12/38 • Number of events 13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	42.9% 3/7 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Mucosal inflammation	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Oedema peripheral	30.8% 4/13 • Number of events 7 • From start of study drug administration up to 90 days after the last dose of MEDI3617	26.2% 11/42 • Number of events 15 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 12 • From start of study drug administration up to 90 days after the last dose of MEDI3617	18.4% 7/38 • Number of events 16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
General disorders Pyrexia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Immune system disorders Drug hypersensitivity	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Infections and infestations Upper respiratory tract infection	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Infections and infestations Urinary tract infection	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Injury, poisoning and procedural complications Contusion	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	18.8% 3/16 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Aspartate aminotransferase increased	7.7% 1/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Blood creatinine increased	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Gamma-glutamyltransferase increased	7.7% 1/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Investigations Weight increased	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	19.0% 8/42 • Number of events 11 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 15 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Decreased appetite	7.7% 1/13 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	19.0% 8/42 • Number of events 11 • From start of study drug administration up to 90 days after the last dose of MEDI3617	31.2% 5/16 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	13.2% 5/38 • Number of events 7 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Dehydration	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 8 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Hypomagnesaemia	7.7% 1/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	42.9% 3/7 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Metabolism and nutrition disorders Hyponatraemia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Arthralgia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	25.0% 4/16 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Back pain	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	18.8% 3/16 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Myalgia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	19.0% 8/42 • Number of events 8 • From start of study drug administration up to 90 days after the last dose of MEDI3617	25.0% 4/16 • Number of events 9 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Musculoskeletal and connective tissue disorders Pain in extremity	7.7% 1/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	50.0% 8/16 • Number of events 10 • From start of study drug administration up to 90 days after the last dose of MEDI3617	10.5% 4/38 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Ataxia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Dizziness	15.4% 2/13 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	31.0% 13/42 • Number of events 14 • From start of study drug administration up to 90 days after the last dose of MEDI3617	43.8% 7/16 • Number of events 10 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Dysgeusia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Headache	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	16.7% 7/42 • Number of events 8 • From start of study drug administration up to 90 days after the last dose of MEDI3617	25.0% 4/16 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	18.4% 7/38 • Number of events 8 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Hypoaesthesia	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Neuropathy peripheral	30.8% 4/13 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.9% 3/38 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Nervous system disorders Paraesthesia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Psychiatric disorders Anxiety	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	25.0% 4/16 • Number of events 6 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Psychiatric disorders Depression	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	18.8% 3/16 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Psychiatric disorders Insomnia	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	25.0% 4/16 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	10.5% 4/38 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Renal and urinary disorders Proteinuria	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	13.2% 5/38 • Number of events 14 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Cough	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	21.4% 9/42 • Number of events 9 • From start of study drug administration up to 90 days after the last dose of MEDI3617	25.0% 4/16 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Dyspnoea	23.1% 3/13 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	21.4% 9/42 • Number of events 12 • From start of study drug administration up to 90 days after the last dose of MEDI3617	18.8% 3/16 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	10.5% 4/38 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	15.4% 2/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/42 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Nasal congestion	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Pleural effusion	23.1% 3/13 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	9.5% 4/42 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Respiratory, thoracic and mediastinal disorders Productive cough	7.7% 1/13 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	5.3% 2/38 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Skin and subcutaneous tissue disorders Alopecia	23.1% 3/13 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.4% 1/42 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Skin and subcutaneous tissue disorders Night sweats	7.7% 1/13 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	6.2% 1/16 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	4.8% 2/42 • Number of events 2 • From start of study drug administration up to 90 days after the last dose of MEDI3617	12.5% 2/16 • Number of events 4 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/38 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/7 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Skin and subcutaneous tissue disorders Rash	0.00% 0/13 • From start of study drug administration up to 90 days after the last dose of MEDI3617	7.1% 3/42 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	0.00% 0/16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	2.6% 1/38 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617	14.3% 1/7 • Number of events 1 • From start of study drug administration up to 90 days after the last dose of MEDI3617
Vascular disorders Hypertension	23.1% 3/13 • Number of events 3 • From start of study drug administration up to 90 days after the last dose of MEDI3617	23.8% 10/42 • Number of events 12 • From start of study drug administration up to 90 days after the last dose of MEDI3617	37.5% 6/16 • Number of events 24 • From start of study drug administration up to 90 days after the last dose of MEDI3617	34.2% 13/38 • Number of events 16 • From start of study drug administration up to 90 days after the last dose of MEDI3617	28.6% 2/7 • Number of events 5 • From start of study drug administration up to 90 days after the last dose of MEDI3617

Additional Information

Mohammed Dar, MD

MedImmune, LLC

Phone: 301-398-0000

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee "MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome" in the agreement description.
Publication restrictions are in place

Restriction type: OTHER